Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04935879 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Phase 3 study of Sickle Cell Disease and Vaso-occlusive Crisis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 241
- Enrollment target
- 20
- Study locations
NCT04935879 is a Phase 3 study of Sickle Cell Disease and Vaso-occlusive Crisis that has completed, run by Pfizer. The registered enrollment target is 241 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT04935879, a Phase 3 study of Sickle Cell Disease and Vaso-occlusive Crisis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 241 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Inclacumab
Study Locations (20)
Illinois
- Hospital Pharmacy Services- Investigational Drug Services - Chicago
- Rush University Medical Center Investigator Pharmacy - Chicago
- Rush University Medical Center - Chicago
- University of Illinois Clinical Research Center (CRC) - Chicago
- University of Illinois Hospital and Health Sciences System(UI Health) - Chicago
Alabama
- University of South Alabama Children's and Women's Hospital - Mobile
- University of South Alabama Mitchell Cancer Institute - Mobile
- University of South Alabama Strada Patient Care Center - Mobile
California
- UC Irvine Health - Orange
- UCI Center for clinical research - Orange
Massachusetts
- Dana-Farber Cancer Institute IDS Pharmacy - Boston
- Dana-Farber Cancer Institute - Boston
North Carolina
- Duke University Medical Center - Durham
- DUMC Investigational Drug Services Pharmacy - Durham
Texas
- McGovern Medical School/Health Science Center Houston - Houston
- Memorial Hermann - TMC Investigational Drugs, IDS Pharmacy - Houston
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Uconn Health/Uconn John Dempsey Hospital/Neag Comprehensive Cancer Center/New England Sickle Cell - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2024-06-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04935879
The ClinicalTrials.gov registry entry for NCT04935879 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (17% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04935879 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Illinois, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT04935879 about?
NCT04935879 is a clinical study titled "A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises". This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receiv...
What is the current status of trial NCT04935879?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 241 participants. The study started on 2021-10-04. Estimated completion is 2024-06-06.
What conditions does trial NCT04935879 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-Occlusive Pain Episode in Sickle Cell Disease.
What interventions are being tested in trial NCT04935879?
The interventions under investigation include: Placebo (DRUG), Inclacumab (DRUG).
Who is sponsoring clinical trial NCT04935879?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04935879 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RECRUITING · Phase 3
-
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
RECRUITING · Phase 3
-
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
RECRUITING · Phase 3
-
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
RECRUITING · Phase 3
-
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.